Association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis

Zhang HongXia; Guo LiPing; Zhou Lu; Wang BangMao

doi:10.3969/j.issn.1001-5256.2018.04.025

Issue 4

Apr. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(4): 820-824

PDF( 1825 KB)

Association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2018.04.025

Department of Gastroenterology, General Hospital of Tianjin Medical University

Research funding:

Published Date: 2018-04-20

Abstract

Abstract

Objective To evaluate the association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis (AIH) , and to analyze the influencing factors for the rapidity of response.Methods A retrospective analysis was performed on 61 AIH patients with long-term follow-up, who visited The General Hospital of Tianjin Medical University from November 2001 to May 2017.These patients were divided into five groups according to the time for transaminase to decrease to a normal level:< 3 months group, 3-6 months group, 6-12 months group, 12-24 months group, and > 24 months group.The chi-square test was used to compare the rate of progression to cirrhosis and sustained response rate between these groups.One-way analysis of variance and the two-independent-samples t test were used to analyze the influencing factors for the rapidity of response.The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and one-way analysis of variance was used for comparison between multiple groups; the chi-square test was used for comparison of categorical data between two groups, and the contingency table chi-square test was used for comparison between multiple groups.Results The < 3 months group had the lowest proportion of patients with progression to cirrhosis (20%) ; all of the two patients in the > 24 months group progressed to cirrhosis; and 62.5% of the patients in the 12-24 months group progressed to cirrhosis.The rate of progression to cirrhosis was significantly lower in the patients who showed response within 3 months than in those who showed no response within 3 months (20% vs 48.15%, χ2= 5.067, P < 0.05) .The rates of progression to cirrhosis for the < 3 months group, 3-6 months group, 6-12 months group, 12-24 months group, and > 24 months group were 20%, 41.7%, 20%, 62.5%, and 100%, respectively, and the < 3 months group had a significantly lower rate of progression to cirrhosis than the 12-24 months group and > 24 months group (χ2= 5.546 and 6.400, both P < 0.05) .The sustained response rate of the < 3 months group was significantly higher than that of the 12-24 months group and > 24 months group (χ2= 4.322, P < 0.05) .Conclusion For AIH patients, the rapidity of response is associated with progression to cirrhosis; a rapid response reduces the rate of progression to cirrhosis.Responding within 3 months may indicate a good outcome, while responding beyond 1 year may indicate a poor outcome.Initial alanine aminotransferase level, and therapeutic drugs may influence the rapidity of response.
- hepatitis, autoimmune,
- liver cirrhosis,
- prognosis

FullText(HTML)

References(19)

References

[1]European Association for the Study of the Liver.EASL clinical practice guidelines:autoimmune hepatitis[J].J Hepatol, 2015, 63 (4) :971-1004.

[2]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and management of autoimmune hepatitis (2015) [J].J Clin Hepatol, 2016, 32 (1) :9-22. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2016, 32 (1) :9-22.

[3]CZAJA AJ, MANNS MP.Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis[J].Gastroenterology, 2010, 139 (1) :58-72.

[4]CZAJA AJ.Rapidity of treatment response and outcome in type 1autoimmune hepatitis[J].J Hepatol, 2009, 51 (1) :161-167.

[5]WANG Q, QIU D, MA X.Early normalization of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients[J].Aliment Pharmacol Ther, 2011, 34 (1) :107-109.

[6]ALVAREZ F, BERG PA, BIANCHI FB, et al.International Autoimmune Hepatitis Group report:review of criteria for diagnosis of autoimmune hepatitis[J].J Hepatol, 1999, 31 (5) :929-938.

[7]LUTH S, HERKEL J, KANZLER S, et al.Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis[J].J Clin Gastroenterol, 2008, 42 (8) :926-930.

[8]CZAJA AJ.Advances in the current treatment of autoimmune hepatitis[J].Dig Dis Sci, 2012, 57 (8) :1996-2010.

[9]GLEESON D, HENEGHAN MA, British Society of Gastroenterology.British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis[J].Gut, 2011, 60 (12) :1611-1629.

[10]FRIEDMAN SL.Liver fibrosis—from bench to bedside[J].J Hepatol, 2003, 38 (Suppl 1) :s38-s53.

[11]LIEBER CS.Prevention and treatment of liver fibrosis based on pathogenesis[J].Alcohol Clin Exp Res, 1999, 23 (5) :944-949.

[12]PINZANI M, ROINBOUTS K.Liver fibrosis:from the bench to clinical targets[J].Dig Liver Dis, 2004, 36 (4) :231-242.

[13]TAKIGAWA T, MIYAZAKI H, KINOSHITA M, et al.Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice[J].Am J Physiol Gastrointest Liver Physiol, 2013, 305 (6) :427-438.

[14]YASUHIRO M, YOSHIAKI I, HARUHIKO K, et al.Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis[J].Hepatol Int, 2009, 3 (4) :556-562.

[15]LI YR, WANG WB, ZHANG LY, et al.The analysis of efficacy of glycyrrhizin therapy for autoimmune hepatitis[J].J Clin Hepatol, 2007, 23 (2) :117-118. (in Chinese) 李蕴铷, 王文冰, 张黎颖, 等.甘草酸类药物治疗自身免疫性肝炎疗效分析[J].临床肝胆病杂志, 2007, 23 (2) :117-118.

[16]Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases.Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J].J Clin Hepatol, 2016, 32 (5) :844-852. (in Chinese) 甘草酸制剂肝病临床应用专家委员会.甘草酸制剂肝病临床应用专家共识[J].临床肝胆病杂志, 2016, 32 (5) :844-852.

[17]SELVARAJAH V, MONTANO-LOZA AJ, CZAJA AJ.Systematic review:managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs[J].Aliment Pharmacol Ther, 2012, 36 (8) :691-707.

[18]LIU L, LI XD, XIAO MZ, et al.Correlation analysis of autoantibodies and biochemical indicators in patients with autoimmune hepatitis typeⅠ[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (2) :14-18. (in Chinese) 刘玲, 李晓东, 肖明中, 等.自身免疫性肝炎Ⅰ型患者自身抗体与血清生物化学指标的相关性分析[J/CD].中国肝脏病杂志:电子版, 2016, 8 (2) :14-18.

[19]QIU DK, MA X, SHENG L.Study on strengthening the response to the treatment of autoimmune hepatitis[J].Chin J Dig, 2013, 33 (1) :2-4.邱德凯, 马雄, 盛黎.加强对自身免疫性肝炎治疗应答的研究[J].中华消化杂志, 2013, 33 (1) :2-4.

Relative Articles

[1]	Zhang HaiPing, Yan HuiPing. Research advances in autoantibodies in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 749-753. doi: 10.3969/j.issn.1001-5256.2020.04.007
[2]	Cui NaNa, Wang QiXia. Diagnosis and differential diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 724-727. doi: 10.3969/j.issn.1001-5256.2020.04.002
[3]	Wang Rui, Wang QiXia, Ma Xiong. Standard therapy and potential therapeutic targets for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 737-742. doi: 10.3969/j.issn.1001-5256.2020.04.005
[4]	Wang QiXia, Ma Xiong. Current status and perspectives of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 721-723. doi: 10.3969/j.issn.1001-5256.2020.04.001
[5]	Jin Chao, Pan JieLu, Yu Xiao, Zhang HaiYan, Xing LianJun. Advances in the clinical treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2331-2334. doi: 10.3969/j.issn.1001-5256.2019.10.044
[6]	Xue Mei, Shen Yi, Shen MengYi, Fan XiaoLi, Men RuoTing, Yang Li. Autoimmune hepatitis-related autoantibodies and their clinical significance[J]. Journal of Clinical Hepatology, 2019, 35(6): 1392-1396. doi: 10.3969/j.issn.1001-5256.2019.06.048
[7]	Chen Jie, Huang ChunYang, Dan Jing, Liu YanMin. Role of autoimmune ecological factors in the pathogenesis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2339-2341. doi: 10.3969/j.issn.1001-5256.2019.10.046
[8]	Chen Jie, Liu YanMin, Huang ChunYang, Huang YunLi, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liao HuiYu, Han Ying, Dan Jing. Clinical features of autoimmune hepatitis in children: An analysis of 10 cases[J]. Journal of Clinical Hepatology, 2018, 34(10): 2164-2168. doi: 10.3969/j.issn.1001-5256.2018.10.020
[9]	Sheng JianHui, Sun Li, Tan HuiYing, Tan YouWen. Roxithromycin-induced autoimmune hepatitis:a case report[J]. Journal of Clinical Hepatology, 2018, 34(5): 1086-1087. doi: 10.3969/j.issn.1001-5256.2018.05.032
[10]	Hu ZhiChao, Fan XiaoLi, Shen Yi, Yang Li. Current status and recent progress of second-line drugs for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(5): 1119-1122. doi: 10.3969/j.issn.1001-5256.2018.05.042
[11]	Li YanQing, Dong HongJing, Liu XiaoWen, Gao YanHang. Latest clinical advances in autoimmune hepatitis in special populations and special types of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1338-1342. doi: 10.3969/j.issn.1001-5256.2018.06.044
[12]	Gao XiaoQin, Zhao YongXun, Ren Qian, Zhou YongNing. Research advances in drug-induced autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2222-2225. doi: 10.3969/j.issn.1001-5256.2017.11.038
[13]	Zhong QiHua, Zhou GuiQin, Wang XianBo, Wang XiaoJing, Wang RongBing, Sun FengXia. Research advances in non-hormonal therapies for autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2016, 32(2): 378-381. doi: 10.3969/j.issn.1001-5256.2016.02.040
[14]	Zhang Jun, Wang QiXia, Ma Xiong. Advances in immunological treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1874-1877. doi: 10.3969/j.issn.1001-5256.2016.10.010
[15]	Wang QianYi, Jia JiDong. Advances in diagnosis and treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 160-162. doi: 10.3969/j.issn.1001-5256.2015.02.003
[16]	Lu Jun. Three cases of drug-induced autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2014, 30(5): 449-450. doi: 10.3969/j.issn.1001-5256.2014.05.017
[17]	Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007
[18]	Qiu DeKai. Diagnosis and treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(5): 321-322.
[19]	Shu HuiJun, Zhu Feng, Zhang LiXian. Comparison of the simplified criteria and conventional criteria for the diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2011, 27(9): 980-984.
[20]	Wang TaiLing, Zhao XinYan. Pathological features of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2011, 27(6): 577-580.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	杨鸣，李艳敏. 自身免疫性肝炎患者免疫球蛋白水平与肝脏炎症程度相关性. 社区医学杂志. 2021(14): 857-860 .
2.	户梅芳. 肝功能和自身抗体检查在自身免疫性肝炎诊断中的应用探讨. 淮海医药. 2019(01): 62-64 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2324) PDF downloads(351)

Association between the rapidity of response and progression to cirrhosis in patients with autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2018.04.025